Is WeGovy the Same as Ozempic?

With all the increased hype regarding Ozempic’s game changing results in weight loss, there has been some confusion about whether WeGovy and Ozempic are the same medication. Both drugs have the same active ingredient, semaglutide. Where the difference lies is in who the medication is marketed to and generally prescribed for.

Start your medical weight loss journey today

Here at Bodyline, we can help you understand the similarities between WeGovy and Ozempic to help you get clued up for a medical weight loss journey.


Most of the differences between WeGovy and Ozempic come from the way each medication is marketed. Ozempic was created and originally marketed towards people living with type 2 diabetes, however when using the medication on people with obesity researchers found that Ozempic had an incredibly positive effect on weight. That’s why the pharmaceutical manufacturer, Novo Nordisk, decided to remarket the product as a weight loss medication with the brand name WeGovy.

Start your medical weight loss journey today

Despite the differences in intentions and marketing, Ozempic is perfectly fine to be used by non-diabetics for weight loss. 

Active Ingredients

Both WeGovy and Ozempic contain the active ingredient semaglutide. This is a GLP-1 receptor agonist, meaning it works by increasing insulin secretion in the stomach lining and by lowering glucagon secretion. This helps to regulate blood sugar levels and can improve glycaemic control in people with type 2 diabetes.

However, semaglutide also impacts the appetite centre of the brain, curbing hunger pangs and cravings in order to help users remain in a caloric deficit and increase chances of successful weight loss. When Ozempic is used alongside a supported nutritional and active lifestyle change, the results can be incredible.


While marketing differs, one of the main distinctions between WeGovy and Ozempic is the dosage. WeGovy is available in a higher dose than Ozempic, with a maximum dose of 2.4 mg compared to Ozempic’s maximum dose of 1.0 mg.


WeGovy and Ozempic are both administered once weekly through subcutaneous injection. They come in the form of slimming pens and offer a dose that lasts throughout the week for appetite suppression and blood sugar control. In this sense, Wegovy and Ozempic are the same when administered.

Available with Bodyline Wellness Clinics

At Bodyline, we offer Ozempic along a supported medical wellness programme that has seen success from over 100,000 customers across the UK. Support is incredibly important when taking weight loss medication, as clinical weight loss through Ozempic isn’t magic, it also requires hard work and dedication.

With over 17 years of experience in supporting clients reach their ultimate goal weight, we’re thrilled to be able to offer Ozempic’s amazing results for our customers. Get in touch today to start your medical weight loss programme with Bodyline by calling 0800 995 6036 or filling in our online contact form.

Are they the same?

In conclusion, WeGovy and Ozempic are pretty much the same medication, however they are not the same medication when marketed by their pharmaceutical manufacturers and have different dosages.

Related blog posts

By now we should all have heard of the incredible weight loss results from GLP-1 receptor agonist medications and their ever-growing popularity. All over the UK, people are searching for access to ‘game changing’ medications to solve their weight problems. Searches for semaglutide, tirzepatide and liraglutide (brand names WeGovy/Ozempic, Mounjaro, and Saxenda respectively) have increased dramatically in the past year, and interest continues to rise. That’s because for the first time ever, there seems to be a potential long-term solution to the obesity epidemic that has afflicted the world over the past 30 years.
Despite the enormous popularity of WeGovy and its incredible impact on weight loss, a shortage of the injectable weight loss therapy has been ongoing in recent months. The semaglutide-containing injection has been dubbed “game-changing” for the treatment of obesity, and demand has been high, but manufacturer Novo Nordisk has struggled to keep up and has only released limited stock.
Mounjaro, also known as tirzepatide, is an innovative prescription medication that has shown great potential in promoting weight loss in clinical trials. Due to rising levels of obesity, and therefore increasing need for treatments, many people are rushing to try game-changing medications like Mounjaro to solve their problems.


Contact Bodyline to find out more how we can treat and support you to improve your health and wellbeing.

"*" indicates required fields

Select the Bodyline treatment that you would like to discuss*
By submitting this form you agree to the Bodyline privacy policy.